International Journal of Health Policy and Management

International Journal of Health Policy and Management

Priority Setting in HIV, Tuberculosis, and Malaria – New Cost-Effectiveness Results From WHO-CHOICE

Document Type : Original Article

Authors
Ambinintsoa H. Ralaidovy 1, 2
Jeremy Addison Lauer 1, 3
Carel Pretorius 4
Olivier JT Briët 5, 6
Edith Patouillard 1
1 World Health Organization (WHO), Geneva, Switzerland
2 CERDI-CNRSIRD-UCA, Clermont-Ferrand, France
3 University of Strathclyde, Glasgow, UK
4 Avenir Health, Glastonbury, CT, USA
5 Swiss Tropical and Public Health Institute, Basel, Switzerland
6 University of Basel, Basel, Switzerland
10.34172/ijhpm.2020.251
Abstract
Background
This paper forms part of an update of the World Health Organization Choosing Interventions that are Cost-Effective (WHO-CHOICE) programmes. It provides an assessment of global health system performance during the first decade of the 21st century (2000-2010) with respect to allocative efficiency in HIV, tuberculosis (TB) and malaria control, thereby shining a spotlight on programme development and scale up in these Millennium Development Goal (MDG) priority areas; and examining the cost-effectiveness of selected best-practice interventions and intervention packages commonly in use during that period.
 
Methods
Generalized cost-effectiveness analysis (GCEA) was used to determine the cost-effectiveness of the selected interventions. Impact modelling was performed using the OpenMalaria platform for malaria and using the Goals and TIME (TB Impact Model and Estimates) models in Spectrum for HIV and TB. All health system costs, regardless of payer, were included and reported in international dollars. Health outcomes are estimated and reported as the gain in healthy life years (HLYs) due to the specific intervention or combination. Analysis was restricted to eastern sub-Saharan Africa and Southeast Asia.
 
Results
At the reference year of 2010, commonly used interventions for HIV, TB and malaria were cost-effective, with cost-effectiveness ratios less than I$ 100/HLY saved for virtually all interventions included. HIV, TB and malaria prevention and treatment interventions are highly cost-effective and can be implemented through a phased approach to full coverage to achieve maximum health benefits and contribute to the progressive elimination of these diseases.
 
Conclusion
During the first decade of the 21st century (2000-2010), the global community has done well overall for HIV, TB, and malaria programmes as regards both economic efficiency and programmatic selection criteria. The role of international assistance, financial and technical, arguably was critical to these successes. As the global community now tackles the challenge of universal health coverage, this analysis can reinforce commitment to Sustainable Development Goal targets but also the importance of continued focus on these critical programme areas.
Keywords
Cost-Effectiveness Analysis
HIV
Tuberculosis
Malaria
Priority Setting
Universal Health Coverage

 

"Watch the Video Summary"

 

  Check the full list of "WHO-CHOICE" special issue here. 

  1. United Nations. Sustainable development knowledge platform: 3. Ensure healthy lives and promote well-being for all at all ages. https://sdgs.un.org/goals/goal3. Accessed August 14, 2017. Published 2016.
  2. World Health Organization (WHO). Health, the SDGs and the Role of Universal Health Coverage: Next Steps in the South-East Asia Region, To Reach Those Being Left Behind. Regional Office for South-East Asia; 2016.
  3. World Health Organization (WHO). Making Fair Choices on the Path to Universal Health Coverage: Final Report of the WHO Consultative Group on Equity and Universal Health Coverage. Geneva: WHO; 2014.
  4. Verguet S, Kim JJ, Jamison DT. Extended cost-effectiveness analysis for health policy assessment: a tutorial. Pharmacoeconomics. 2016;34(9):913-923. doi:10.1007/s40273-016-0414-z
  5. Hogan DR, Baltussen R, Hayashi C, Lauer JA, Salomon JA. Cost effectiveness analysis of strategies to combat HIV/AIDS in developing countries. BMJ. 2005;331(7530):1431-1437. doi:10.1136/bmj.38643.368692.68
  6. Morel CM, Lauer JA, Evans DB. Cost effectiveness analysis of strategies to combat malaria in developing countries. BMJ. 2005;331(7528):1299. doi:10.1136/bmj.38639.702384.AE
  7. Baltussen R, Floyd K, Dye C. Cost effectiveness analysis of strategies for tuberculosis control in developing countries. BMJ. 2005;331(7529):1364. doi:10.1136/bmj.38645.660093.68
  8. Institute for Health Metrics and Evaluation. Global Health Data Exchange_Countries.  http://ghdx.healthdata.org/countries. Accessed January 16, 2017.
  9. World Health Organization (WHO). World Malaria Report 2018. WHO; 2018.
  10. Evans DB, Lim SS, Adam T, Edejer TT. Evaluation of current strategies and future priorities for improving health in developing countries. BMJ. 2005;331(7530):1457-1461. doi:10.1136/bmj.38658.675243.94
  11. Evans DB, Edejer TT, Adam T, Lim SS. Methods to assess the costs and health effects of interventions for improving health in developing countries. BMJ. 2005;331(7525):1137-1140. doi:10.1136/bmj.331.7525.1137
  12. Institute for Health Metrics and Evaluation. Global Burden of Disease 2010 Study Published. London: The Lancet; 2012.
  13. Hutubessy R, Chisholm D, Edejer TT. Generalized cost-effectiveness analysis for national-level priority-setting in the health sector. Cost Eff Resour Alloc. 2003;1(1):8. doi:10.1186/1478-7547-1-8
  14. Smith T, Killeen GF, Maire N, et al. Mathematical modeling of the impact of malaria vaccines on the clinical epidemiology and natural history of Plasmodium falciparum malaria: overview. Am J Trop Med Hyg. 2006;75(2 Suppl):1-10. doi:10.4269/ajtmh.2006.75.2_suppl.0750001
  15. Lauer JA, Röhrich K, Wirth H, Charette C, Gribble S, Murray CJ. PopMod: a longitudinal population model with two interacting disease states. Cost Eff Resour Alloc. 2003;1(1):6. doi:10.1186/1478-7547-1-6
  16. Briët OJ, Penny MA, Hardy D, et al. Effects of pyrethroid resistance on the cost effectiveness of a mass distribution of long-lasting insecticidal nets: a modelling study. Malar J. 2013;12:77. doi:10.1186/1475-2875-12-77
  17. Corbel V, Chabi J, Dabiré RK, et al. Field efficacy of a new mosaic long-lasting mosquito net (PermaNet 3.0) against pyrethroid-resistant malaria vectors: a multi centre study in Western and Central Africa. Malar J. 2010;9:113. doi:10.1186/1475-2875-9-113
  18. Van Bortel W, Chinh VD, Berkvens D, Speybroeck N, Trung HD, Coosemans M. Impact of insecticide-treated nets on wild pyrethroid resistant Anopheles epiroticus population from southern Vietnam tested in experimental huts. Malar J. 2009;8:248. doi:10.1186/1475-2875-8-248
  19. Howes RE, Dewi M, Piel FB, et al. Spatial distribution of G6PD deficiency variants across malaria-endemic regions. Malar J. 2013;12:418. doi:10.1186/1475-2875-12-418
  20. Ross A, Maire N, Molineaux L, Smith T. An epidemiologic model of severe morbidity and mortality caused by Plasmodium falciparum. Am J Trop Med Hyg. 2006;75(2 Suppl):63-73. doi:10.4269/ajtmh.2006.75.63
  21. Goodman C, Coleman P, Mills A. Economic Analysis of Malaria Control in Sub-Saharan Africa. Geneva: Global Forum for Health Research; 2000.
  22. World Health Organization (WHO). World Malaria Report 2012. WHO; 2012.
  23. Briët OJ, Hardy D, Smith TA. Importance of factors determining the effective lifetime of a mass, long-lasting, insecticidal net distribution: a sensitivity analysis. Malar J. 2012;11:20. doi:10.1186/1475-2875-11-20
  24. Penny M, Galactionova E, Tediosi F, et al. Public Health Impact and Cost-Effectiveness of the RTS,S Malaria Vaccine: Modelling and Simulation Results. Basel: Swiss TPH; 2013.
  25. Brïet O, Galactionova K, Ross A, et al. Report on the generation of matrices with per-capita, age- and time-specific event rates for ‘null’, ‘current’ and ‘intervention’ scenarios, by country endemic for P. vivax for WHO sub-regions SEAR-D, EMR-D and SEAR-B, according to revised methodology. Internal report: unpublished. December 2015.
  26. Briët O, Galactionova K. Report on the generation of matrices with per-capita, age- and time-specific event rates for ‘null,’ ‘current’ and ‘intervention’ scenarios, by country endemic for P. falciparum for WHO sub-regions Afr-D and Afr-E, and other malaria endemic countries situated in Africa, according to revised methodology. Internal report: unpublished. December 2015.
  27. Spectrum [computer program]. https://avenirhealth.org/software-spectrum.php.
  28. Stover J. Projecting the demographic consequences of adult HIV prevalence trends: the Spectrum Projection Package. Sex Transm Infect. 2004;80 Suppl 1:i14-18. doi:10.1136/sti.2004.010157
  29. Stover J, Bollinger L, Avila C. Estimating the impact and cost of the WHO 2010 recommendations for antiretroviral therapy. AIDS Res Treat. 2011;2011:738271. doi:10.1155/2011/738271
  30. Stover J, Fidzani B, Molomo BC, Moeti T, Musuka G. Estimated HIV trends and program effects in Botswana. PLoS One. 2008;3(11):e3729. doi:10.1371/journal.pone.0003729
  31. Stover J, Hallett TB, Wu Z, et al. How can we get close to zero? the potential contribution of biomedical prevention and the investment framework towards an effective response to HIV. PLoS One. 2014;9(11):e111956. doi:10.1371/journal.pone.0111956
  32. Stover J, Korenromp EL, Blakley M, et al. Long-term costs and health impact of continued global fund support for antiretroviral therapy. PLoS One. 2011;6(6):e21048. doi:10.1371/journal.pone.0021048
  33. Stover J, Bollinger L. Financial resources required to achieve universal access to HIV prevention, treatment, care and support. Description of Interventions/Services Included in the Estimates of Resources Needed for HIV and AIDS. Methodological Annex–IV. Glastonbury, CT: Avenir Health; 2007.
  34. Bollinger LA. How can we calculate the "E" in "CEA"? AIDS. 2008;22 Suppl 1:S51-57. doi:10.1097/01.aids.0000327623.31856.45
  35. Avenir Health. Goals Manual: A Model for Estimating the Effects of Interventions and Resource Allocation on HIV Infections and Deaths. Glastonbury, CT: Avenir Health; 2011.
  36. Bollinger L, Perham K, DeCormier Plosky W. Grading Goals: A Systematic Review of Studies in the Goals Model. Vienna: Paper presented at: Abstract no. WEPE0817; 2010.
  37. World Health Organization (WHO). Guidelines for Conducting HIV Surveillance Among Pregnant Women Attending Antenatal Clinics Based on Routine Programme Data. Geneva: WHO; 2015.
  38. The DHS program: Data. https://dhsprogram.com/data/available-datasets.cfm. Accessed 2014.
  39. UNAIDS. UNAIDS Data. http://www.unaids.org/en/resources/documents/2017/2017_data_book.
  40. Houben RM, Lalli M, Sumner T, et al. TIME Impact-a new user-friendly tuberculosis (TB) model to inform TB policy decisions. BMC Med. 2016;14:56. doi:10.1186/s12916-016-0608-4
  41. World Health Organization (WHO). Systematic Screening for Active Tuberculosis: Principles and Recommendations. WHO; 2013.
  42. Vassall A, van Kampen S, Sohn H, et al. Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden countries: a cost-effectiveness analysis. PLoS Med. 2011;8(11):e1001120. doi:10.1371/journal.pmed.1001120
  43. van’t Hoog AH, Langendam MW, Mitchell E, Sinclair D, Leeflang M, Lonnroth K,. A Systematic Review of the Sensitivity and Specificity of Symptom and Chest Radiography Screening for Active Pulmonary Tuberculosis in HIV-Negative Persons and Persons with Unknown HIV Status. Geneva: WHO; 2013.
  44. World Health Organization (WHO). WHO End TB Strategy: Global strategy and targets for tuberculosis prevention, care and control after 2015. World Health Organization; 2015.
  45. Stop TB Partnership. The Global Plan to End TB. Stop TB Partnership; 2015.
  46. World Health Organization (WHO). Global Tuberculosis Report 2015. WHO; 2015.
  47. World Health Organization (WHO). Publicly available TB database of the Global TB Program. http://www.who.int/tb/country/data/download/en/. Accessed 2014.
  48. World Health Organization (WHO). Global Health Sector Strategy on HIV, 2016-2021. WHO; 2016.
  49. World Health Organization (WHO). Consolidated Guidelines on HIV Prevention, Diagnosis, Treatment and Care for Key Populations. WHO; 2016.
  50. World Health Organization (WHO). Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach. WHO; 2016.
  51. World Health Organization (WHO). Consolidated Guidelines on HIV Testing Services. WHO; 2015.
  52. World Health Organization (WHO). Guidelines on HIV Self-Testing and Partner Notification. WHO; 2016.
  53. World Health Organization (WHO). Implementing the End TB Strategy: The Essentials. WHO; 2015.
  54. World Health Organization (WHO). Infection Prevention and Control of Epidemic-And Pandemic Prone Acute Respiratory Infections in Health Care. WHO; 2014.
  55. World Health Organization (WHO). Global Tuberculosis Report 2018. Geneva: WHO; 2018.
  56. World Health Organization (WHO). Guidelines for the Treatment of Drug-Susceptible Tuberculosis and Patient Care. WHO; 2017.
  57. World Health Organization (WHO). A Guide to Monitoring and Evaluation for Collaborative TB/HIV Activities. WHO; 2015.
  58. World Health Organization (WHO). Guidelines for Malaria Vector Control. WHO; 2019.
  59. World Health Organization (WHO). Malaria: Intermittent Preventive Treatment in Pregnancy (IPTp). WHO; 2018.
  60. World Health Organization (WHO). WHO Recommendations on Antenatal Care for A Positive Pregnancy Experience. Geneva: WHO; 2016.
  61. World Health Organization (WHO). WHO Policy Recommendation on Intermittent Preventive Treatment During Infancy with Sulphadoxine-Pyrimethamine (IPTi-SP) for Plasmodium Falciparum Malaria Control in Africa. WHO; 2010.
  62. World Health Organization (WHO). WHO Policy Recommendation: Seasonal Malaria Chemoprevention (SMC) for Plasmodium Falciparum Malaria Control in Highly Seasonal Transmission Areas of the Sahel Sub-Region in Africa. WHO; 2012.
  63. World Health Organization (WHO). Guidelines for the Treatment of Malaria. 3rd ed. Geneva: WHO; 2015.
  64. Bertram MY, Stenberg K, Brindley C, et al. Disease control programme support costs: an update of WHO-CHOICE methodology, price databases and quantity assumptions. Cost Eff Resour Alloc. 2017;15:21. doi:10.1186/s12962-017-0083-6
  65. World Health Organization (WHO). Immunization Costing & Financing: A Tool and User Guide for Comprehensive Multi-Year Planning (‎cMYP)‎. Geneva: WHO; 2006.
  66. World Health Organization (WHO). Voluntary Medical Male Circumcision for HIV Prevention in 14 Priority Countries in East and Southern Africa: WHO Progress Brief. WHO; 2017.
  67. Hankins C, Forsythe S, Njeuhmeli E. Voluntary medical male circumcision: an introduction to the cost, impact, and challenges of accelerated scaling up. PLoS Med. 2011;8(11):e1001127. doi:10.1371/journal.pmed.1001127
  68. World Health Organization (WHO). Preparation for the third high-level meeting of the General Assembly on the prevention and control of non-communicable diseases, to be held in 2018: Report by the Director-General. WHO; 2016.
  69. World Health Assembly. Follow-Up to the Political Declaration of the High-Level Meeting of the General Assembly on the Prevention and Control of Non-Communicable Diseases: Sixty-Fourth. Geneva: World Health Assembly; 2013.
  70. Tan-Torres Edejer T, Baltussen R, Adam T, et al. Making Choices in Health: WHO Guide to Cost-effectiveness Analysis. Geneva: WHO; 2003.

XML
PDF 1.14 M
Supplementary File
(IJHPM does not take responsibility for any information provided in the supplementary files.)
Ralaidovy-Supple-File-1-IJHPM.pdf
Ralaidovy-Supple-File-2-IJHPM.pdf

  • Received Date 21 December 2019
  • Revised Date 30 November 2020
  • Accepted Date 07 December 2020
  • First Published Date 03 January 2021
  • Published Date 01 November 2021